This week saw a major victory for cancer patients and advocates who fought to regain control of their genes. But in the fast-changing world of medical research, who will own the rights to future discoveries? The High Court ruling against patenting BRCA1 means Myriad Genetics no longer own the mutation test and scientists outside the company will be able to extend research into the breast cancer gene, explains health editor Amy Corderoy.